Indivior Pharmaceuticals, Inc. (INDV)
NASDAQ: INDV · Real-Time Price · USD
38.62
-0.20 (-0.52%)
Aug 10, 2026, 10:40 AM EDT - Market open
Indivior Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Indivior Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $49. The average 1-year stock price forecast is 26.88% higher than the current stock price, while the lowest is $43 (+11.34%) and the highest is $53 (+37.23%).
Price Target: $49 (+26.88%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Indivior Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 3 |
| Buy | 2 | 1 | 1 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $46 → $43 | Buy | Maintains | $46 → $43 | +11.34% | Aug 5, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Reiterates $50 → $53 | Buy | Reiterates | $50 → $53 | +37.23% | Aug 4, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $48 | Buy | Reiterates | $48 | +24.29% | Aug 4, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $54 → $59 | Buy | Reiterates | $54 → $59 | +52.77% | May 22, 2026 |
| Northland Securities | Northland Securities | Buy Maintains $50 | Buy | Maintains | $50 | +29.47% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
1.33B
from 1.24B
Increased by 7.12%
Revenue Next Year
1.36B
from 1.33B
Increased by 2.62%
EPS This Year
4.43
from 2.50
Increased by 77.32%
EPS Next Year
4.61
from 4.43
Increased by 3.92%
EPS and Forward PE are based on non-GAAP adjusted numbers.